Zhejiang Hisoar Pharmaceutical (002099.SZ) released its performance for the first half of the year, with a net income of 38.1025 million yuan, an increase of 98.74%.

Zhejiang Hisoar Pharmaceutical (002099.SZ) released the 2024 interim report, with the company's revenue at 10.39...

Zhongtong Finance and Economics APP news, Zhejiang Hisoar Pharmaceutical (002099.SZ) released the 2024 interim report, with the company's revenue at 1.039 billion yuan, a decrease of 13.17% year-on-year. The net income attributable to the shareholders of the listed company was 38.1025 million yuan, an increase of 98.74% year-on-year. The net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 30.8509 million yuan, a decrease of 56.73% year-on-year. The basic earnings per share was 0.02 yuan.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

海翔药业(002099.SZ)发布上半年业绩，净利润3810.25万元，增长98.74%

Zhejiang Hisoar Pharmaceutical (002099.SZ) released its performance for the first half of the year, with a net income of 38.1025 million yuan, an increase of 98.74%.

Risk Disclaimer

Statement